Best Allergy Nasal Sprays 2026 Reference Edition

EXPLAINER

Should You Use Intranasal Steroids Long-Term? Yes — Here's Why

What 20+ years of RCT, cohort, and meta-analysis data actually show.

By BestAllergyNasalSprays Team Reviewed by BestAllergyNasalSprays Team
Content updated Evidence reviewed First published

Literature review current through

TL;DR

Yes, daily intranasal corticosteroid (INCS) use is supported by 20+ years of RCT and cohort data and is recommended as first-line therapy for persistent allergic rhinitis. The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis 5 Guideline Growth-velocity and HPA-axis concerns are real but molecule- and dose-specific: newer fluticasone furoate and mometasone furoate have systemic bioavailability under 1%. Older fluticasone propionate and triamcinolone have larger but still small effects. The right answer is informed daily use, not avoidance.

The honest answer

Patients who Google “are nasal steroids safe long term” land on a wall of contradictory advice — usually some mix of “they’re addictive” (false: see our rebound page), “they cause cataracts” (the inhaled-steroid concern, applied incorrectly), and “they stunt growth” (a real signal, mostly with older molecules at higher doses). The honest answer requires distinguishing the molecules.

The pharmacology that matters: Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids Expert Fluticasone furoate is similar. Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage) Expert Triamcinolone acetonide has about 46% — an order of magnitude higher, though still well below an oral steroid course. Systemic exposure tracks bioavailability. So when a patient asks “is this safe long-term?”, the answer depends on which spray you mean.

The other thing worth saying: the harm of not treating allergic rhinitis is real. Untreated chronic rhinitis is associated with worse asthma control, more sinus infections, sleep-disordered breathing, and decreased quality of life. The risk of daily INCS is small and well-characterized. The risk of foregoing therapy in someone with persistent disease is larger, less precisely measurable, and almost always under-discussed.

What the evidence says

The pediatric growth-velocity question is where the literature is most informative — because it’s where you’d expect to detect a small systemic steroid signal first.

Intranasal corticosteroids: long-term safety evidence
StudyDesignn / populationFindingTier
Schenkel 2002 [1]Double-blind RCT, 1 yrChildren 3.5–9 yr, n=98, FP 200 mcg/dayNo growth suppression vs placebo (CI within ±0.8 cm/yr)RCT
Skoner 2003 [2]Controlled trialChildren, INCS triamcinolone vs FPDetectable but small short-term bone-growth signal; no HPA axis suppression at on-label dosesRCT
Mener 2015 [3]Meta-analysisPediatric pooled dataSmall statistically detectable but clinically minor growth-velocity reduction; mainly older moleculesMeta-analysis
Bielory 2015 [9]Safety reviewPediatric INCS overviewNewer molecules (FF, mometasone) safer than older FP/triamcinoloneTier 1
StatPearls [8]Clinical referenceAdult fluticasone useDecades of safety data for adults and children ≥4 yrTier 2
In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child’s clinician 3 Expert Intranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience 8 Expert

The HPA-axis question for adults: at on-label INCS doses, the data show no clinically meaningful cortisol suppression. The signal that does emerge in the literature comes from supratherapeutic dosing or from concurrent inhaled corticosteroid use. Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion 5 Guideline

The mechanism is also worth re-stating because it explains why these drugs work and why side-effects are local-dominant. Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release 4 Expert Common side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review 6 Expert

The triamcinolone caveat: In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed Expert Even with its higher bioavailability, the 1-year safety data are reassuring at on-label doses.

Where Allermi fits

For adults who need daily control and may benefit from a multi-active formulation, allergist-monitored compounded therapy is one of the cleaner safety patterns: lower individual doses, regular monitoring, formula adjustments. Allermi is designed for sustained daily use, with a prescribing allergist reviewing your response and adjusting your formula as needed Expert

Allermi uses an FDA-approved corticosteroid (typically triamcinolone) as the daily-control engine, paired with one or more on-label active ingredients per the patient’s symptom profile. The allergist titrates over time. Eligibility: 13+ in 39 US states (18+ in AK/NM/OR/SC; not in AR/DE/KS/MS/WV/ND/RI/DC); not prescribed in pregnancy or breastfeeding. Eligibility quiz. For OTC users, the equivalent pattern is: pick a low-bioavailability molecule (mometasone or fluticasone furoate), use proper technique, and reassess yearly.

Summary & recommendations

Summary & Recommendations

  1. Daily INCS use is supported by 20+ years of RCT and cohort data; first-line per Dykewicz 2020.
  2. Choose a molecule with low systemic bioavailability for long-term daily use: mometasone (<0.1%) or fluticasone furoate (~0.5%).
  3. In children, the small growth-velocity signal is real but mostly historical (older fluticasone propionate, triamcinolone). Monitor height annually.
  4. HPA-axis suppression at on-label adult doses is rare and clinically silent.
  5. Technique matters: aim outward toward the ear, never at the septum (reduces epistaxis and septum injury).
  6. Reassess yearly with your clinician. Do not stop a working INCS for vague safety concerns without a substitution plan.

Publish history

Publish history

  • Initial publication.

References

Regulatory & label

  1. DailyMed: Flonase SPL · FDA DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c

Guidelines

  1. Dykewicz 2020: Rhinitis Practice Parameter · JACI (2020) https://pubmed.ncbi.nlm.nih.gov/32707227/
  2. StatPearls: Fluticasone · NIH Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK547701/

Primary literature

  1. Schenkel 2002: 1-yr fluticasone propionate, no growth suppression · PubMed (2002) https://pubmed.ncbi.nlm.nih.gov/12528607/
  2. Skoner 2003: INCS bone growth + HPA axis in children · PubMed (2003) https://pubmed.ncbi.nlm.nih.gov/12546339/
  3. Mener 2015: INCS growth velocity meta-analysis · PubMed (2015) https://pubmed.ncbi.nlm.nih.gov/25367369/
  4. Mygind: INCS rhinitis review · PubMed https://pubmed.ncbi.nlm.nih.gov/11577794/
  5. Mometasone bioavailability <0.1% · PubMed (2001) https://pubmed.ncbi.nlm.nih.gov/15114430/
  6. INCS safety in children review · PubMed (2015) https://pubmed.ncbi.nlm.nih.gov/25751851/

Related

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.